Neogen (NEOG) is voluntarily recalling all lots within expiry of Neogen Vet Hycoat Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of 10 mL/50 mg product vials. Neogen received a number of reports of adverse events in horses following intraarticular injections of this product, which is inconsistent with its labeled, intended use. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use. While the company’s investigation into this issue is ongoing, out of an abundance of caution the 2mL/20mg product vials are also being recalled. The company is proactively working with the FDA on this matter. This product is labeled as a sterile solution, but due to microbial contamination of certain lots, the recalled lots should no longer be considered sterile. The risk is particularly acute when used as an intraarticular injection, inconsistent with its labeled, intended use. No other Neogen products are affected by this field action.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEOG:
- Neogen price target raised to $10 from $6.50 at Piper Sandler
- Neogen price target raised to $12 from $8 at Guggenheim
- Neogen Earnings Call Marks Early Turnaround Momentum
- Midday Fly By: Defense stocks surge on Trump budget request
- Morning Movers: Neogen skyrockets following Q2 results and raised FY26 guidance
